Roivant Sciences Ltd at Bank of America Global Healthcare Conference Transcript
Good morning, everyone. Welcome to the BofA Healthcare Conferences. My name is Chi. I work with Jason Gerberry, who is the senior analyst here covering SMid Biotech and Spec Pharma and we are pleased to host Roivant Sciences today. And we have here with us is Richard Pulik, CFO of the company. Thanks for joining us.
Thank you so much for having me.
So maybe to start off for audience who's not familiar with the company. Maybe talk a little bit about what Roivant Sciences does as a company and the business model that you guys have.
Great. Yes. Thanks again for the invitation and for having us here. Look, Roivant, I would say, has one of the most exciting I&I portfolios out there. We have -- with $15 billion in peak sales potential
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
